Difference between revisions of "BRAF mutation"
Jump to navigation
Jump to search
| Line 2: | Line 2: | ||
==General== | ==General== | ||
*BRAF inhibitors (e.g. vemurafenib) is used to treat BRAF mutation positive tumours.<ref name=pmid29148538>{{Cite journal | last1 = Cheng | first1 = L. | last2 = Lopez-Beltran | first2 = A. | last3 = Massari | first3 = F. | last4 = MacLennan | first4 = GT. | last5 = Montironi | first5 = R. | title = Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. | journal = Mod Pathol | volume = 31 | issue = 1 | pages = 24-38 | month = 01 | year = 2018 | doi = 10.1038/modpathol.2017.104 | PMID = 29148538 }}</ref> | *Clinical implication: BRAF inhibitors (e.g. vemurafenib) is used to treat BRAF mutation positive tumours.<ref name=pmid29148538>{{Cite journal | last1 = Cheng | first1 = L. | last2 = Lopez-Beltran | first2 = A. | last3 = Massari | first3 = F. | last4 = MacLennan | first4 = GT. | last5 = Montironi | first5 = R. | title = Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. | journal = Mod Pathol | volume = 31 | issue = 1 | pages = 24-38 | month = 01 | year = 2018 | doi = 10.1038/modpathol.2017.104 | PMID = 29148538 }}</ref> | ||
Prevalence by tumour type:<ref name=pmid29148538/> | ===Prevalence=== | ||
BRAF mutations by tumour type:<ref name=pmid29148538/> | |||
*BRAF mutations in ~ 50% of melanomas; respond to BRAF inhibitors. | *BRAF mutations in ~ 50% of melanomas; respond to BRAF inhibitors. | ||
*BRAF mutations in ~ 10% of colorectal tumours. | *BRAF mutations in ~ 10% of colorectal tumours. | ||
Revision as of 18:16, 23 January 2019
BRAF mutation is a common genetic change in cancer.
General
- Clinical implication: BRAF inhibitors (e.g. vemurafenib) is used to treat BRAF mutation positive tumours.[1]
Prevalence
BRAF mutations by tumour type:[1]
- BRAF mutations in ~ 50% of melanomas; respond to BRAF inhibitors.
- BRAF mutations in ~ 10% of colorectal tumours.
- Poor prognosticator, poor response to chemotherapy, typically right sided tumours.
- BRAF mutations in ~45-50% of papillary thyroid carcinoma.
- BRAF mutations in ~3% of lung adenocarcinomas.